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Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL), is an aggressive disease 
with considerable biological and clinical heterogeneity. 
Standard first-line treatment is combination chemo-
therapy with cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) or an equivalent regimen 
combined with rituximab (R). This results in a com-
plete remission (CR) rate of 75% to 80% and a 3- to 
5-year progression-free survival (PFS) of 50% to 80%. 
The addition of R to CHOP chemotherapy has been 
the most significant step in recent years in improving 
overall survival (OS) and PFS rates. Current treatment 
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BACkgROunD AnD OBjECtIvEs: relapsed, histologically aggressive non-hodgkin lymphoma (nhl) has a 
poor prognosis; relapsed patients who do not respond to second line therapy or are unfit for bmt have a worse 
prognosis. angiogenesis is increased in aggressive nhl and could be targeted by selective cyclooxygenase-2 in-
hibition and metronomic chemotherapy. We assessed the toxicity of metronomic chemotherapy and the response 
and progression-free survival in patients with relapsed/refractory diffuse large b-cell lymphoma (dlbcl).
PAtIEnts AnD MEthODs: We prospectively studied 41 patients with a diagnosis of relapsed and/or refractory 
dlbcl who may have received any number of preceding therapies (as long as one included an anthracycline) 
and were not candidates for bone marrow transplantation. they received oral cyclophosphamide (50 mg every 
day), oral methotrexate (2.5 mg 4 times/week) and high-dose oral celecoxib (400 mg twice daily) until there was 
disease progression or unacceptable toxicity.
REsuLts: all 41 patients (median age, 56 years) were evaluable for toxicity and response, with a median fol-
low up of 9.1 months (range, 4-35 months). at relapse, 51.2% had a high international prognostic index. the 
treatment protocol was well tolerated with no major toxicities. the most common toxicities were fatigue (61%), 
nausea (22%), neutropenia (19.5%), and anemia (22%). in 31.7 % there was a partial response and 48.8% had 
stable disease. progression-free survival was 12 months. the median response duration was 10 months. 
COnCLusIOns: We conclude that metronomic chemotherapy can be used for patients with relapsed and or 
refractory dlbcl with reasonable outcome and acceptable toxicity. standard approaches such as hematopoietic 
stem cell transplantation and chemo-immunotherapy combinations should be explored prior to a decision on 
metronomic chemotherapy.
with CHOP-R results in an improvement in PFS and 
OS by 15% to 20% compared to CHOP chemotherapy 
alone.1
Despite this major therapeutic advance, a significant 
proportion of patients will relapse or remain refractory 
to initial chemoimmunotherapy. The PARMA trial 
confirmed the place of high-dose chemotherapy and 
autologous hematopoietic stem cell transplantation 
(aHSCT) as the optimum salvage treatment. In this 
trial, chemotherapy-sensitive patients were random-
ized to further salvage chemotherapy with cytarabine/
platinum-based chemotherapy alone, or in combina-
tion with aHCT. Event-free survival (EFS) and OS at 
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5 years in the transplant arm were 46% and 53%, re-
spectively, compared with 12% and 32% in the chemo-
therapy alone arm.2
Numerous salvage chemotherapy regimens have 
been used to treat relapsed or refractory DLBCL pa-
tients. The majority are based on agents that demon-
strate non-cross-resistance to those used in primary 
therapy. Broadly speaking, they can be divided into 
regimens based on ifosfamide, cytarabine/platinum, or 
gemcitabine. Studies on salvage therapy have generally 
included all patients with aggressive lymphoma and are 
not restricted to DLBCL subtype.3
Recent data indicate that angiogenesis is important 
in the pathophysiology and prognosis of aggressive his-
tologic subtypes of NHL. Angiogenesis is a multistep 
process that leads to the formation of new blood ves-
sels from existing vasculature and is associated with 
the growth and dissemination of malignant tumors.4 
Angiogenesis and angiogenic factors are increased in 
most lymphomas. In addition, angiogenesis has been 
associated with adverse outcomes or more aggressive 
clinical behavior in malignant lymphoma. However, the 
role of angiogenesis might vary in lymphoma subtypes 
because of the prognostic value of microvessel density 
and the different expression of angiogenesis-related 
molecules in the various lymphoma subtypes.5
Metronomic chemotherapy refers to the frequent, 
even daily, administration of chemotherapeutics at dos-
es significantly below the maximum tolerated dose, with 
no prolonged drug-free breaks.6 Much evidence, mostly 
in vitro, indicates that the ‘activated’ endothelial cells of 
newly forming blood-vessel capillaries are highly and 
selectively sensitive to very low doses of various chemo-
therapeutic drugs.7
The findings of Wun et al8 reveal that human Burkitt-
type B-cell lymphoma cell lines express elevated levels 
of cyclooxygenase 2 (COX-2), and this fits with earlier 
studies indicating that B-lineage cells are capable of ex-
pressing COX-2. COX-2 is a prostaglandin synthase 
enzyme that has been implicated in tumorigenesis. One 
of the proposed mechanisms by which this may occur 
is by stimulating angiogenesis through the production 
of proangiogenic factors including vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor, 
platelet-derived growth factor, transforming growth 
factor-h1, and endothelin-1. COX-2 inhibitors, such 
as celecoxib, have been shown to reduce the incidence 
of neoplastic lesions in familial adenomatous polypo-
sis and therefore may have a role in the treatment of 
established malignancies. Furthermore, COX-2 is 
overexpressed in some lymphomas and is of potential 
prognostic importance. These preclinical data provide 
the rationale for using low-dose chemotherapy together 
with a selective COX-2 inhibitor in the treatment of ag-
gressive NHL.9
PAtIEnts AnD MEthODs
From March 2006 to June 2009, 41 patients with re-
lapsed or refractory DLBCL were enrolled in this phase 
II study. The primary objective was to determine the re-
sponse rate to oral high-dose celecoxib combined with 
daily oral low-dose cyclophosphamide and low-dose 
methotrexate continuous administration in this patient 
population. The secondary objectives were to define the 
toxicity of the given regimen and PFS. Patients were 
considered eligible if they had relapsed after any num-
ber of preceding therapies (as long as one had included 
an anthracycline) and had a projected life expectancy 
of >4 months. Patients who relapsed following au-
tologous HSCT were eligible. Patients were excluded 
from the study if they were transplant eligible, receiving 
concurrent chemotherapy or radiotherapy (including 
corticosteroids) or had received any other antineoplas-
tic therapy within the preceding 2 weeks. Patients with 
Eastern Cooperative Oncology Group performance 
status of >3, uncontrolled hypertension, and unstable 
cardiovascular or significant renal or hepatic disease 
were also excluded. As celecoxib is a sulphonamide, pa-
tients with a proven allergy to sulfa drugs were also ex-
cluded. Adequate hematologic (hemoglobin count >85 
g/L; absolute neutrophil count >1,000/mm3; platelet 
count >75,000/mm3), renal, and hepatic functions 
were mandatory. All eligible patients had at least one 
bidimensionally measurable target lesion. Our institu-
tional review board approved this study and informed 
consent was obtained from each patient.
Pretreatment evaluations included a complete histo-
ry and physical examination, routine laboratory evalua-
tion, and CT of the chest, abdomen, and pelvis as well 
as bone marrow biopsy. Patients were clinically assessed 
by physical exam and blood work monthly until pro-
gression. CT scans were repeated for response evalu-
ation every 2 months or sooner if clinically indicated. 
Patients were followed off-study until death.
All patients received oral celecoxib 400 mg twice 
daily (with food), oral cyclophosphamide 50 mg daily, 
and oral methotrexate 2.5 mg four times a week. In 
cases of nausea and vomiting (> grade 3), dyspepsia, or 
abdominal pain or a 50% increase in serum creatinine 
or liver enzymes, celecoxib was reduced (200 mg orally 
twice daily, then 100 mg orally twice daily). The need 
for further dose reduction or gastrointestinal bleeding 
resulted in discontinuation within the study. Similarly, 
cyclophosphamide could be reduced twice (to 25 mg 
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orally daily, then 25 mg orally on alternate days) for 
grade >3 neutropenia or thrombocytopenia. No dose 
escalations were permitted. Toxicity was assessed ac-
cording to Common Terminology Criteria for Adverse 
Event v3.0 (CTCAE) (December 12, 2003). Response 
to treatment was assessed according to the criteria of 
Cheson et al.10
An objective response consisted of complete clinical 
response, complete clinical response unconfirmed, or a 
partial response. Progression of disease was determined 
by an increase of 50% in the product of perpendicu-
lar diameters of the index lesions or the appearance of 
new lesions. All other patients were considered to have 
stable disease.
Because antiangiogenic therapy is cytostatic, and in 
many preclinical models of metronomic chemotherapy, 
tumors may initially grow before they stabilize and 
sometimes regress, patients were allowed to remain in 
the study for up to 4 months if radiologic or clinical tu-
mor progression was asymptomatic and not a threat to 
vital organ function.
Data were analyzed using the SPSS program for 
Windows version 11. PFS was estimated using the 
Kaplan-Meier method. Results were considered signifi-
cant at the 5% critical level (P< .05).
REsuLts
This prospective study included 41 patients with refrac-
tory or relapsed DLBCL who presented at the Menofia 
University Hospital, Clinical Oncology Department be-
tween March 2006 and June 2009, and were followed 
until the end of December 2009. All patients had mea-
surable disease. The time from last relapse ranged from 1 
to 10 months with a median of 1.5 months. For patients 
who received one line of treatment for relapse, the time 
from last relapse ranged from 3 to 10 months with a me-
Table 1. Patient characteristics at enrollment.
No. of patients (%)
   Sex
      male 21 (51.2%)
      Female 20 (48.8%)
   age
      median 57 years
      range 38-78 years
   no. of prior chemotherapy regimens 
   for relapse
      One line 9 (22%)
      Two lines  11 (27%)
      Three lines 3 (7%)
   international prognostic index (iPi) 
   at enrollment
       low iPi 3 (7.3%)
       low intermediate iPi 7 (17.07%)
      High intermediate iPi 21 (51.2%)
      High iPi 10 (24.4%)
Table 2. Toxicity in 41 patients.
Grade I Grade II Grade III Grade IV Total
   nausea 7 (17.1) 2 (4.9) - - 9 (22.0)
   Dyspepsia 8 (19.5) 2  (4.9) - - 10 (24.4)
   anemia 7 (17.1) 2 (4.9) - - 9 (22.0)
   neutropenia 7 (17.1) 1  (2.4) 8 (19.5)
   Thrombocytopenia 4 (9.7) - - - 4 (9.7)
   Skin rash 3  (7.3) - - - 3  (7.3)
   Fatigue or weakness 14 (34.1) 10 (24.4) 1 (2.4) - 25 (60.9)
   Serum creatinine elevation 3 (7.3) - - - 3 (7.3)
values are numbers (percentages)
dian of 8 months. For patients who received 2 lines of 
treatment for relapse, the time from last relapse ranged 
from 1 to 9 months with a median of 3 months. For the 
three patients who received three lines, the time from the 
last relapse ranged from 1 to 6 months (Table 1).
There was significant correlation between the num-
ber of prior protocols and the time to relapse. Patients 
who received only one line for relapse had a longer time 
to relapse (P<.05). There was significant correlation be-
tween PFS and age (Kendall’s tau test). The number of 
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prior chemotherapy protocols given for relapse did not 
statistically affect PFS in our study.
Toxicity was evaluated according to the National 
Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 3.0 
(Table 2). Fatigue was the most common side effect 
with 14 patients (34.1%) having grade I fatigue, 10 pa-
tients (24.4%) having grade II fatigue, and one patient 
(2.4%) having grade III fatigue. No dose reduction or 
interruption to treatment was necessary except for the 
patient with grade III fatigue in which treatment was 
interrupted for one week and then resumed at the usu-
al dose. Gastrointestinal toxicities were mild, ranging 
from grade I to grade II with no grade III or IV tox-
icities observed, except for 2 patients who had grade 
III oral mucositis. Both patients had undergone prior 
whole neck irradiation for treatment of cervical lymph 
nodes. Metronomic chemotherapy had to be stopped 
for two weeks until the condition improved.
Two patients had grade I edema (mostly nutri-
tional) that responded to a short course of diuretics 
and nutrition support with no treatment interruption. 
There was no cardiac toxicity observed during the fol-
low-up period of this study. Two patients had grade I 
hepatic toxicity in the form of elevated liver enzymes, 
but no permanent drug reduction was needed for tox-
icity management.
Table 3. response rates.
   Response rate
   Complete response 1  (2.4%)
   Partial response 13 (31.7%)
   Stationary disease 20 (48.8%)
   Progressive disease 7  (17.1%)
Figure 1. Progression-free survival.
Four of the 7 patients who had progressed (Table 
3) died due to progressive disease while the other 3 
were shifted to another line of chemotherapy. Among 
the patients with a partial response, 5 patients ulti-
mately progressed while on therapy at a median of 9 
months, with a range of 6 to 12 months. Eight patients 
with stable disease developed a progressive course at a 
median of 8.5 months. Patients who progressed were 
shifted to another line of treatment or kept on best 
supportive care depending on their general condition.
 The median actuarial PFS was 20 months (95% 
confidence interval, 13.9-26.0 months) (Figure 1). 
There was a significant correlation between PFS and 
age (P=.04) that was a continuous factor observed. 
There was no significant correlation between PFS 
and time from last relapse, number of prior lines of 
chemotherapy or time from last treatment. Also, there 
was no significant correlation between IPI score and 
PFS (P=.07).
DIsCussIOn
Targeting angiogenesis has also been investigated in 
the Southwest Oncology Group S0108 study of the 
anti-VEGF monoclonal antibody, bevacizumab, in 
patients with relapsed DLBCL. A clinical non-pro-
gression rate of 25% was observed for the 51 patients 
in this study, with a median time to progression of 5 
months (range 4 to 18 months).11 In our study, we 
have shown that the combination of continuous low-
dose cyclophosphamide and methotrexate with high-
dose celecoxib resulted in a response rate of 32.5% in 
a group of pretreated patients with relapsed DLBCL. 
The combination was well tolerated, with a low inci-
dence of hematologic, gastrointestinal, and renal tox-
icity. There is only one published study on the use of 
metronomic chemotherapy in treatment of relapsed 
NHL by Buckstein et al9 in which 32 patients with 
relapsed or refractory NHL were enrolled to receive 
high-dose celecoxib 400mg twice daily and low-dose 
oral cyclophosphamide 50 mg daily. Only 20 patients 
had relapsed or refractory DLBCL, while the others 
had anaplastic lymphoma, T-cell lymphoma or trans-
formed follicular lymphoma. Most patients were heav-
ily pretreated, with a median of three prior chemo-
therapy regimens (range, 1-7). Eleven patients (34%) 
had relapsed after aHSCT. In our study, in which 
we added methotrexate 2.5 mg four times/week, all 
patients had relapsed or refractory DLBCL with no 
other pathological types. None of our patients had re-
ceived aHSCT.
Only one patient in our study achieved complete 
remission, which occurred after 14 months of treat-
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ment, while 31.7% and 48.8% achieved partial re-
sponse and stable disease, respectively.
In our study, the median actuarial PFS was 20 
months (95% CI, 13.9-26.0 months) compared to the 
Buckstein study9 in which the median actuarial PFS 
was 4.7 months (95% CI, 2.5-9.2). In our study, only 
three patients had grade I skin rash which developed 
months after initiation of treatment and responded to 
anti-allergic treatments; no interruption of the pro-
gram was needed. Fatigue was a common side effect. 
No thrombotic events were observed in our study.
 We conclude that metronomic chemotherapy can 
be used for patients with relapsed and or refractory 
DLBCL with reasonable outcome and acceptable tox-
icity. Standard lines such as HST and chemo-immu-
notherapy combinations should be explored prior to 
a decision on metronomic chemotherapy. We recom-
mend a longer follow up to evaluate the late toxicities 
of a metronomic chemotherapy schedule. Although 
there were no thromboembolic events recorded in this 
study, it is important to closely monitor the patients 
for these events as they are exposed to high levels of 
celecoxib. We suggest a study involving a larger num-
ber of patients that correlates clinical response with 
VEGF blood levels and also to determine COX-2 
receptor status before and during treatment to assess 
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